| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,674,000 |
| Market
Cap: |
60.96(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2298 - $2.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 707 |
| Guru Rank Value : 1.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
816,825 |
816,825 |
| Total Buy Value |
$0 |
$0 |
$194,885 |
$194,885 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
4 |
4 |
| Total Shares Sold |
267,396 |
267,396 |
419,842 |
597,458 |
| Total Sell Value |
$170,773 |
$170,773 |
$340,560 |
$1,013,893 |
| Total People Sold |
5 |
5 |
6 |
9 |
| Total Sell Transactions |
10 |
10 |
23 |
42 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-08-10 |
4 |
AS |
$14.75 |
$32,450 |
I/I |
(2,200) |
448,378 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-07-25 |
4 |
AS |
$15.97 |
$43,283 |
I/I |
(2,700) |
450,578 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-07-24 |
4 |
AS |
$16.89 |
$47,421 |
I/I |
(2,800) |
453,278 |
|
- |
|
| Haqq Christopher |
EVP, R&D & Chief Scientific Of |
• – – |
2017-07-17 |
4 |
AS |
$14.92 |
$89,520 |
D/D |
(6,000) |
362,080 |
|
- |
|
| Haqq Christopher |
EVP, R&D & Chief Scientific Of |
• – – |
2017-06-15 |
4 |
AS |
$12.65 |
$75,900 |
D/D |
(6,000) |
368,080 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2017-06-09 |
4 |
AS |
$13.15 |
$13,150 |
D/D |
(1,000) |
107,374 |
|
- |
|
| Dobmeier Eric |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
12,500 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
27,298 |
|
- |
|
| Seidenberg Beth C |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
13,689 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
108,374 |
|
- |
|
| Marcus Joel S |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
7,000 |
|
- |
|
| Heiden William K |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
7,000 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-05-31 |
4 |
AS |
$13.26 |
$45,747 |
I/I |
(3,450) |
456,078 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-05-30 |
4 |
AS |
$13.44 |
$46,368 |
I/I |
(3,450) |
459,528 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-05-18 |
4 |
AS |
$14.94 |
$35,856 |
I/I |
(2,400) |
462,978 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-05-17 |
4 |
AS |
$14.88 |
$35,712 |
I/I |
(2,400) |
465,378 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2017-05-16 |
4 |
AS |
$15.25 |
$18,056 |
D/D |
(1,184) |
103,374 |
|
- |
|
| Mcgrath John |
EVP & Chief Financial Officer |
• – – |
2017-05-16 |
4 |
AS |
$15.27 |
$30,540 |
D/D |
(2,000) |
117,460 |
|
- |
|
| Clark Mitchall G. |
EVP & Chief R & QA Officer |
• – – |
2017-05-16 |
4 |
AS |
$15.25 |
$59,063 |
D/D |
(3,873) |
153,000 |
|
- |
|
| Soffer Gad |
EVP & Chief Strategy Officer |
• – – |
2017-05-16 |
4 |
AS |
$15.19 |
$86,188 |
D/D |
(5,674) |
264,409 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2017-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,366 |
104,558 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2017-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,602 |
22,298 |
|
- |
|
| Ciechanover Isaac E. |
Chief Executive Officer |
• • – |
2017-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,908 |
731,859 |
|
- |
|
| Mcgrath John |
EVP & Chief Financial Officer |
• – – |
2017-05-15 |
4 |
AS |
$14.95 |
$29,900 |
D/D |
(2,000) |
119,460 |
|
- |
|
| Mcgrath John |
EVP & Chief Financial Officer |
• – – |
2017-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,633 |
121,460 |
|
- |
|
736 Records found
|
|
Page 19 of 30 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (1.28%) 
